Published: October 2023
On 27 October 2023, Pfizer and BioNTech report favorable outcomes from the early stage of their joint mRNA vaccine trials targeting both COVID-19 and influenza. The companies noted strong immune responses and safety profiles consistent with their COVID-19 vaccine in Phase I and II trials. They anticipate commencing a critical Phase III trial for these primary formulations in the near future. This mRNA vaccine has the potential to streamline immunization practices worldwide, offering the convenience of a single injection to mitigate the impact of two respiratory diseases for providers, patients, and healthcare systems.
According to Roots Analysis, the mRNA therapeutics and vaccine market is estimated to be worth $51 billion in 2022 and is expected to grow at steady rate during the forecast period.
For detailed insights about this domain, check out our report on mRNA Therapeutics and Vaccine Market or email firstname.lastname@example.org
You may also be interested in the following titles:
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES